Compare JPMorgan Equity Premium Income ETF (JEPI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Pfizer Inc — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.71 (market cap $45.55B), while Pfizer Inc trades at $27.72 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 3.5× JPMorgan Equity Premium Income ETF's market cap, and Pfizer Inc pays a 6.18% dividend while JPMorgan Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 56 Days and Pfizer Inc for 158 Days on average.
| JEPI | PFE | |
|---|---|---|
Market Cap | $45.55B | $158.56B |
Volume | 3,820,809 | 44,138,282 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $29.02 |
52-Week Low | $55.29 | $23.67 |
Typical Hold Time | 56 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.45, down 0.16% with a bearish technical outlook. The ETF maintains consistent monthly dividend distributions, with recent payments of $0.37 in August and September 2026. Technical indicators show bearish momentum with selling pressure in moving averages, while oscillators remain neutral. The fund continues to attract income-focused investors seeking monthly payouts through its covered call strategy.
The outlook remains cautious given the bearish technical signals and market volatility. Income investors may find value in the consistent dividend stream, but capital appreciation potential appears limited in the current technical environment. Key risks include market direction sensitivity and interest rate impacts on income strategies.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
